🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “Syndax” Clear

  1. Revumenib

    Syndax Pharmaceuticals Inc

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial

  2. Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib

    Syndax Pharmaceuticals Inc

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  3. AXATILIMAB

    Syndax Pharmaceuticals Inc

    Chronic graft versus host disease (cGVHD)

    phase 2 small molecule active

    1 trial

  4. AXATILIMAB, Placebo

    Syndax Pharmaceuticals Inc

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  5. Atezolizumab

    Syndax Pharmaceuticals Inc

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  6. Axatilimab

    Syndax Pharmaceuticals Inc

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Azacitidine

    Syndax Pharmaceuticals Inc

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Durvalumab

    Syndax Pharmaceuticals Inc

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. Entinostat

    Syndax Pharmaceuticals Inc

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    2 trials

  10. Entinostat

    Syndax Pharmaceuticals Inc

    Melanoma

    phase 2 small molecule completed

    1 trial

  11. Entinostat

    Syndax Pharmaceuticals Inc

    ER+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Entinostat

    Syndax Pharmaceuticals Inc

    Renal Cell Carcinoma

    phase 2 small molecule active

    2 trials

  13. Entinostat

    Syndax Pharmaceuticals Inc

    Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  14. Entinostat

    Syndax Pharmaceuticals Inc

    Non-Small-Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Entinostat

    Syndax Pharmaceuticals Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  16. Entinostat

    Syndax Pharmaceuticals Inc

    Metastatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  17. Fulvestrant

    Syndax Pharmaceuticals Inc

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. Pembrolizumab

    Syndax Pharmaceuticals Inc

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  19. Pembrolizumab

    Syndax Pharmaceuticals Inc

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  20. Revumenib

    Syndax Pharmaceuticals Inc

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  21. Revumenib

    Syndax Pharmaceuticals Inc

    Relapsed Adult AML

    phase 2 small molecule active

    1 trial

  22. Revumenib

    Syndax Pharmaceuticals Inc

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Revumenib

    Syndax Pharmaceuticals Inc

    Leukemia

    phase 2 small molecule active

    1 trial

  24. Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613

    Syndax Pharmaceuticals Inc

    Relapsed or Refractory Acute Leukemias

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources